Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 19/20 | 0.79 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.60 |
| ▸ | FPR2 | P25090 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305142 | 0.79 | ENPP1 (0.74) | ENPP1ENPP3ENPP2FPR2 | |
| SCHEMBL20305107 | 0.78 | ENPP1 (0.73) | ENPP1ENPP3ENPP2FPR2 | |
| SCHEMBL20679598 | 0.78 | ENPP1 (1.00) | ENPP1 | |
| SCHEMBL20687568 | 0.77 | ENPP1 (0.72) | ENPP1ENPP3ENPP2FPR2 | |
| SCHEMBL12635995 | 0.76 | SMN1; SMN2 (0.80) | ENPP1 | |
| SCHEMBL24498961 | 0.76 | ENPP1 (0.61) | ENPP1ENPP3ENPP2FPR2 | |
| SCHEMBL24846414 | 0.76 | TDP1 (0.57) | ENPP1 | |
| SCHEMBL20679574 | 0.74 | ENPP1 (1.00) | ENPP1 | |
| SCHEMBL20687583 | 0.74 | ENPP1 (0.86) | ENPP1FPR2 | |
| SCHEMBL30675603 | 0.74 | ENPP1 (1.00) | ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200085782-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | MAVUPHARMA, INC. | 2020-03-19 | — | — | US | claimed |
| US-20200085828-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | ABBVIE INC. | 2020-03-19 | — | — | US | claimed |
| EP-3558352-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | Mavupharma, Inc. (US) | 2019-10-30 | — | — | EP | claimed |
| EP-3558319-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | Mavupharma, Inc. (US) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119325-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | MAVUPHARMA, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2018119328-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | MAVUPHARMA, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20210023234-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210023234-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC (US) | 2021-01-28 | — | — | US | disclosed |
| US-20200085828-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | ABBVIE INC. | 2020-03-19 | — | — | US | disclosed |
| US-20200085782-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | MAVUPHARMA, INC. | 2020-03-19 | — | — | US | disclosed |
| EP-3558319-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | Mavupharma, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558352-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | Mavupharma, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| WO-2018119325-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | MAVUPHARMA, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119328-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | MAVUPHARMA, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ENPP1, ENPP3, ENPEP | ENPP1 1/4885ENPP3 2/4885ENPP2 5/4885 |
| US-20200085782-A1 | COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION | STING1, CGAS, IRF3 | ENPP1 105/4885ENPP3 208/4885ENPP2 123/4885 |
| US-20200085828-A1 | PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT | CGAS, STING1, IRF3 | ENPP1 75/4885ENPP3 142/4885ENPP2 79/4885 |
| US-20210023234-A1 | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ENPP1, ENPP3, PNKP | ENPP1 1/4885ENPP3 2/4885ENPP2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.